. 1972 Oct 7;23(41):1415-7.

[Behavior of uremic hyperlipemia and disturbances of glucose tolerance under chronic intermittent hemodialysis treatment]

[Article in German]

[Article in German]

W Hübner et al. Med Welt. 1972.

. 1972 Oct 7;23(41):1415-7.

No abstract available

Similar articles

Glucose, insulin and glucagon response to intravenous glucose load in patients on chronic hemodialysis.
Shasha SM, Nusem D, Kanter Y, Weiner F. Shasha SM, et al. Isr J Med Sci. 1988 Jan;24(1):15-9. Isr J Med Sci. 1988. PMID: 3279011
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L. Brandi L. Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
Coronary risk in patients with endstage renal disease: interaction of hypertension with hyperlipidemia.
Goldberg AP, Tindira C, Harter HR. Goldberg AP, et al. J Cardiovasc Pharmacol. 1982;4 Suppl 2:S257-61. J Cardiovasc Pharmacol. 1982. PMID: 6177969 No abstract available.
[Aspects of carbohydrate metabolism in chronic uremic patients treated with periodic hemodialysis: determination of phosphoremia during some dynamic tests].
Redaelli B, Salvadeo A, Imbasciati E, Ponticelli C. Redaelli B, et al. Arch Ital Urol Nefrol. 1967;39(6):459-67. Arch Ital Urol Nefrol. 1967. PMID: 5606789 Italian. No abstract available.
[Mortality in patients with chronic renal insufficiency undergoing hemodialysis. Hyperlipemia as coadjuvant factor].
Joven J, Vilella E, Brunzell JD. Joven J, et al. Med Clin (Barc). 1991 Jan 26;96(3):110-3. Med Clin (Barc). 1991. PMID: 2033971 Review. Spanish. No abstract available.

[Hepatic galactose elimination lapacity in chronic renal insufficiency (author's transl)].
Wernze H, Wagner F. Wernze H, et al. Klin Wochenschr. 1973 Sep 15;51(18):933-5. doi: 10.1007/BF01468069. Klin Wochenschr. 1973. PMID: 4762194 German. No abstract available.